Vaxxas Publication in PLoS Medicine Reveals Groundbreaking Clinical Research on Broad Potential of Novel High-Density Microarray Patch (HD-MAP)

To Effeciently Deliver Vaccines Directly to the Skin, Enhancing Immunogenicity

Read the full media release below.

Learn more

Posted in — Media Release


You may also like

12 March 2013

Hugh Alsop appointed Hatchtech CEO

27 May 2017

OneVentures makes first investment for the Biomedical Translation Fund

08 October 2012

Vaxxas Initiates Program With Merck to Optimize Delivery of Next Generation Vaccines Utilizing Novel Mechanism for Immune System Activation

19 October 2021

Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis

12 January 2021

Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA®

16 March 2020

OneVentures invests in international software company Phocas, bringing business back to Australia and positioning the company for international expansion

View All

Ventured. Gained.

Subscribe to our Newsletter for the latest updates from 1V.

decor decor decor
decor decor decor decor decor
clear Close